To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC

J Thorac Oncol. 2021 Jun;16(6):894-896. doi: 10.1016/j.jtho.2021.03.004.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • Antibodies, Monoclonal
  • durvalumab
  • EGFR protein, human
  • ErbB Receptors